Pharmacotherapy of endometrial cancer

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 12, 2009, Pages 1939-1951

  Barrena Medel, Nicanor I ^a,b   Bansal, Sharmilee ^a   Miller, David Scott ^c   Wright, Jason D ^a   Herzog, Thomas J ^a  

^a Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^b HOSPITAL DR SÓTERO DEL RÍO   (Chile)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Adjuvant treatment; Chemotherapy; Endometrial cancer; Hormonal therapy

Indexed keywords

AMINOGLUTETHIMIDE; ANABOLIC AGENT; ANTIESTROGEN; AROMATASE INHIBITOR; CARBOPLATIN; CHEMOPROGESTIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXIFLURIDINE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GESTAGEN; GONADORELIN AGONIST; HYDROXYPROGESTERONE ACETATE; IFOSFAMIDE; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; MITOMYCIN C; PACLITAXEL; PIRARUBICIN; PLACEBO; PROGESTERONE; TAMOXIFEN; UFT; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADVANCED CANCER; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; CYTOTOXICITY; DOSE RESPONSE; ENDOMETRIUM CANCER; GASTROINTESTINAL TOXICITY; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; RECURRENCE RISK; RECURRENT CANCER; REVIEW;

ANTINEOPLASTIC AGENTS, HORMONAL; CHEMOTHERAPY, ADJUVANT; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; META-ANALYSIS AS TOPIC; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 68149124344     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903061291     Document Type: Review

References (70)

1. International Agency for Research on Cancer (IARC). World Cancer Report 2008. Lyon: IARC. •• This report provides an updated comprehensive overview on global cancer burden, patterns, diagnosis, causes and prevention.
2. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15(1):10-17
3. Wang J, Wieslander C, Hansen G, et al. Thin endometrial echo complex on ultrasound does not reliably exclude type 2 endometrial cancers. Gynecol Oncol 2006;101(1):120-125 (Pubitemid 43303570)
4. Sorosky JI. Endometrial cancer. Obstet Gynecol 2008;111(2 Pt 1):436-447
5. Creasman WT, Kohler MF, Odicino F, et al. Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. Gynecol Oncol 2004;95(3):593-596 (Pubitemid 39610410)
6. Sehouli J, Koensgen D, Oskay-Ozcelik G, Mustea A. New aspects of adjuvant therapy in endometrial cancer: current standards and future directions. Crit Rev Oncol Hematol 2008;67(3):204-212
7. Hamilton CA, Cheung MK, Osann K, et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer 2006;94(5):642-646 • A large population-based study highlighting the worse prognosis of UPSC compared with other poorly differentiated endometrioid tumors. (Pubitemid 43361894)
8. Mendivil A, Schuler KM, Gehrig PA. Non-endometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypes. Cancer Control 2009;16(1):46-52
9. Creasman WT, Odicino F, Maisonneuve P, et al. Carcinoma of the corpus uteri. J Epidemiol Biostat 2001;6(1):47-86
10. Mariani A, Dowdy SC, Keeney GL, et al. High-risk endometrial cancer subgroups: candidates for target-based adjuvant therapy. Gynecol Oncol 2004;95(1):120-126 • Using several predictors for different types of relapse previously identified by themselves, these authors were able to define a group of patients that accounted for the vast majority of extravaginal recurrences in endometrial cancer. (Pubitemid 39286286)
11. Greven KM, Randall M, Fanning J, et al. Patterns of failure in patients with stage I, grade 3 carcinoma of the endometrium. Int J Radiat Oncol Biol Phys 1990;19(3):529-534 (Pubitemid 20324243)
12. Ayhan A, Taskiran C, Celik C, Yuce K. The long-term survival of women with surgical stage II endometrioid type endometrial cancer. Gynecol Oncol 2004;93(1):9-13 (Pubitemid 38429542)
13. Mariani A, Dowdy SC, Keeney GL, et al. Predictors of vaginal relapse in stage I endometrial cancer. Gynecol Oncol 2005;97(3):820-827 (Pubitemid 40824652)
14. Mariani A, Webb MJ, Keeney GL, et al. Predictors of lymphatic failure in endometrial cancer. Gynecol Oncol 2002;84(3):437-442 (Pubitemid 34211872)
15. Mariani A, Webb MJ, Keeney GL, et al. Endometrial cancer: predictors of peritoneal failure. Gynecol Oncol 2003;89(2):236-242 (Pubitemid 36457871)
16. Mariani A, Webb MJ, Keeney GL, et al. Hematogenous dissemination in corpus cancer. Gynecol Oncol 2001;80(2):233-238
17. Mariani A, Webb MJ, Keeney GL, et al. Surgical stage I endometrial cancer: predictors of distant failure and death. Gynecol Oncol 2002;87(3):274-280 (Pubitemid 36034647)
18. Aalders J, Abeler V, Kolstad P, Onsrud M. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol 1980;56(4):419-427 (Pubitemid 10018299)
19. Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 2000;355(9213):1404-1411
20. Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004;92(3):744-751
21. Lukka H, Chambers A, Fyles A, et al. Adjuvant radiotherapy in women with stage I endometrial cancer: a systematic review. Gynecol Oncol 2006;102(2):361-368 (Pubitemid 44041658)
22. Kong A, Simera I, Collingwood M, et al. Adjuvant radiotherapy for stage I endometrial cancer: systematic review and meta-analysis. Ann Oncol 2007;18(10):1595-1604 • An excellent summary of the best available evidence about the role of external radiotherapy in early-stage endometrial cancer. (Pubitemid 47506245)
23. Johnson N, Cornes P. Survival and recurrent disease after postoperative radiotherapy for early endometrial cancer: systematic review and meta-analysis. BJOG 2007;114(11):1313-1320 (Pubitemid 47609926)
24. Blake P, Swart AM, Orton J, et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet 2009;373(9658):137-146
25. Hirai M, Hirono M, Oosaki T, et al. Adjuvant chemotherapy in stage I uterine endometrial carcinoma. Int J Gynaecol Obstet 2002;78(1):37-44 (Pubitemid 34756768)
26. Aoki Y, Watanabe M, Amikura T, et al. Adjuvant chemotherapy as treatment of high-risk stage I and II endometrial cancer. Gynecol Oncol 2004;94(2):333-339 (Pubitemid 39024535)
27. Kodama J, Seki N, Ojima Y, et al. Efficacy and prognostic implications of administering adjuvant chemotherapy to patients with endometrial cancer that is confined to the uterus. Eur J Obstet Gynecol Reprod Biol 2007;131(1):76-80 (Pubitemid 46283185)
28. Takeshima N, Ota T, Omatsu K, et al. Postoperative adjuvant chemotherapy in surgically staged grade 3 endometrial cancer. Anticancer Res 2008;28(3B):1785-1788 (Pubitemid 351892885)
29. Maggi R, Lissoni A, Spina F, et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. Br J Cancer 2006;95(3):266-271 (Pubitemid 44187586)
30. Susumu N, Sagae S, Udagawa Y, et al. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol 2008;108(1):226-233 • The first RCT that suggests that chemotherapy could be associated with an improvement in survival of a subgroup of early-stage high-risk endometrial cancer patients. (Pubitemid 350299451)
31. Chan JK, Loizzi V, Youssef M, et al. Significance of comprehensive surgical staging in noninvasive papillary serous carcinoma of the endometrium. Gynecol Oncol 2003;90(1):181-185 (Pubitemid 37338095)
32. Hui P, Kelly M, O'Malley DM, et al. Minimal uterine serous carcinoma: a clinicopathological study of 40 cases. Mod Pathol 2005;18(1):75-82 (Pubitemid 40128098)
33. Wheeler DT, Bell KA, Kurman RJ, Sherman ME. Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation. Am J Surg Pathol 2000;24(6):797-806
34. Huh WK, Powell M, Leath CA, et al. Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy. Gynecol Oncol 2003;91(3):470-475 (Pubitemid 38388138)
35. Havrilesky LJ, Secord AA, Bae-Jump V, et al. Outcomes in surgical stage I uterine papillary serous carcinoma. Gynecol Oncol 2007;105(3):677-682 (Pubitemid 46734192)
36. Thomas MB, Mariani A, Cliby WA, et al. Role of systematic lymphadenectomy and adjuvant therapy in stage I uterine papillary serous carcinoma. Gynecol Oncol 2007;107(2):186-189 (Pubitemid 47575712)
37. Kelly MG, O'Malley DM, Hui P, et al. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. Gynecol Oncol 2005;98(3):353-359 (Pubitemid 41169144)
38. Fader AN, Nagel C, Axtell AE, et al. Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes. Gynecol Oncol 2009;112(3):558-562
39. Mcmeekin DS, Filiaci VL, Thigpen JT, et al. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study. Gynecol Oncol 2007;106(1):16-22
40. Randall ME, Filiaci VL, Muss H, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2006;24(1):36-44 •• A landmark work first confirming the oncologic superiority of chemotherapy versus WART in the adjuvant treatment of optimally resected advanced endometrial cancer. (Pubitemid 46630491)
41. Pectasides D, Pectasides E, Economopoulos T. Systemic therapy in metastatic or recurrent endometrial cancer. Cancer Treat Rev 2007;33(2):177-190 (Pubitemid 46343104)
42. Carey MS, Gawlik C, Fung-Kee-Fung M, et al. Systematic review of systemic therapy for advanced or recurrent endometrial cancer. Gynecol Oncol 2006;101(1):158-167 • Summarizes accurately the role that both chemotherapy and hormonal therapy currently have in advanced or recurrent endometrial cancer setting. (Pubitemid 43303577)
43. Humber CE, Tierney JF, Symonds RP, et al. Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration. Ann Oncol 2007;18(3):409-420 (Pubitemid 46359618)
44. Pectasides D, Xiros N, Papaxoinis G, et al. Carboplatin and paclitaxel in advanced or metastatic endometrial cancer. Gynecol Oncol 2008;109(2):250-254
45. Gien L, Kwon J, Oliver TK, Fung-Kee-Fung M. Adjuvant hormonal therapy for stage I endometrial cancer. Curr Oncol 2008;15(3):126-135
46. Martin-Hirsch PL, Jarvis G, Kitchener H, Lilford R. Progestagens for endometrial cancer. Cochrane Database Syst Rev 2000;2:CD001040
47. Urbanski K, Karolewski K, Kojs Z, et al. Adjuvant progestagen therapy improves survival in patients with endometrial cancer after hysterectomy. Results of one-institutional prospective clinical trial. Eur J Gynaecol Oncol 1993;14(Suppl):98-104 (Pubitemid 24052682)
48. Quinn M. Adjuvant medroxyprogesterone acetate in high risk endometrial cancer. Int J Gynecol Cancer 1998;8(5):387-391 (Pubitemid 28541670)
49. Chiva L, Lapuente F, Gonzalez-Cortijo L, et al. Sparing fertility in young patients with endometrial cancer. Gynecol Oncol 2008;111(2 Suppl):S101-4 • A good abridgment about the results that may be obtained with conservative hormonal treatment in endometrial cancer.
50. Ushijima K, Yahata H, Yoshikawa H, et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol 2007;25(19):2798-2803 • A prospective validation of fertility-sparing hormonal therapy in endometrial cancer. (Pubitemid 47123189)
51. Pandya KJ, Yeap BY, Weiner LM, et al. Megestrol and tamoxifen in patients with advanced endometrial cancer: an Eastern Cooperative Oncology Group Study (E4882). Am J Clin Oncol 2001;24(1):43-46 (Pubitemid 32178670)
52. Quinn MA, Campbell JJ. Tamoxifen therapy in advanced/recurrent endometrial carcinoma. Gynecol Oncol 1989;32(1):1-3 (Pubitemid 19029857)
53. Rendina GM, Donadio C, Fabri M, et al. Tamoxifen and medroxyprogesterone therapy for advanced endometrial carcinoma. Eur J Obstet Gynecol Reprod Biol 1984;17(4):285-291 (Pubitemid 14083091)
54. Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol 1999;17(6):1736-1744 (Pubitemid 29269242)
55. Zhang X, Cao B. Exploration for drug therapy in endometrial carcinoma. Chin Med J (Engl) 1996;109(5):356-360 (Pubitemid 26176744)
56. Decruze SB, Green JA. Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. Int J Gynecol Cancer 2007;17(5):964-978 (Pubitemid 47414814)
57. Greven K, Winter K, Underhill K, et al. Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer. Gynecol Oncol 2006;103(1):155-159 (Pubitemid 44374683)
58. Lupe K, Kwon J, D'Souza D, et al. Adjuvant paclitaxel and carboplatin chemotherapy with involved field radiation in advanced endometrial cancer: a sequential approach. Int J Radiat Oncol Biol Phys 2007;67(1):110-116 (Pubitemid 44959483)
59. Alvarez Secord A, Havrilesky LJ, Bae-Jump V, et al. The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer. Gynecol Oncol 2007;107(2):285-291 (Pubitemid 47575727)
60. Hogberg T, Rosenberg P, Kristensen G, et al. A randomized phase-III study on adjuvant treatment with radiation (RT) {+/-} chemotherapy (CT) in early-stage high-risk endometrial cancer (NSGO-EC-9501/EORTC 55991). J Clin Oncol (Meeting Abstracts) 2007;25(18-suppl):5503 •• An RCT demonstrating the therapeutic advantage of chemoradiation over pelvic radiotherapy in high-risk endometrial cancer.
61. Kuoppala T, Maenpaa J, Tomas E, et al. Surgically staged high-risk endometrial cancer: randomized study of adjuvant radiotherapy alone vs. sequential chemo-radiotherapy. Gynecol Oncol 2008;110(2):190-195
62. Delmonte A, Sessa C. Molecule-targeted agents in endometrial cancer. Curr Opin Oncol 2008;20(5):554-559
63. Fujimoto J. Novel therapeutic strategy for uterine endometrial cancers. Int J Clin Oncol 2008;13(5):411-415
64. Gadducci A, Tana R, Cosio S, et al. Molecular target therapies in endometrial cancer: from the basic research to the clinic. Gynecol Endocrinol 2008;24(5):239-249 • A very comprehensive review addressing promising molecular target therapies for endometrial cancer. (Pubitemid 351891652)
65. Homesley HD, Filiaci V, Gibbons SK, et al. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study. Gynecol Oncol 2009;112(3):543-552
66. Daniel AG, Peters WA. Accuracy of office and operating room curettage in the grading of endometrial carcinoma. Obstet Gynecol 1988;71(4):612-614
67. Larson DM, Johnson KK, Broste SK, et al. Comparison of D&C and office endometrial biopsy in predicting final histopathologic grade in endometrial cancer. Obstet Gynecol 1995;86(1):38-42
68. Kinkel K, Kaji Y, Yu KK, et al. Radiologic staging in patients with endometrial cancer: a meta-analysis. Radiology 1999;212(3):711-718 (Pubitemid 29410973)
69. Selman TJ, Mann CH, Zamora J, Khan KS. A systematic review of tests for lymph node status in primary endometrial cancer. BMC Womens Health 2008;8:8 (Pubitemid 351803145)
70. Morice P, Fourchotte V, Sideris L, et al. A need for laparoscopic evaluation of patients with endometrial carcinoma selected for conservative treatment. Gynecol Oncol 2005;96(1):245-248 (Pubitemid 39612444)